Despite the contentious nature of the health reform debate in Congress, there is significant support from many groups—such as business and labor—for changing the practice of health care delivery, reducing costs, improving effectiveness, and covering the uninsured.
You are here
P&T® Journal contents for September 2009
Stakes High for Pharmaceutical Industry Sectors
A Comparison with Other Oral Antidiabetic Agents
In a study of a largely minority population of diabetic Medicaid recipients, rosi- glitazone (Avandia) was linked to an increase in myocardial infarction and stroke, whereas pioglitazone (Actos) and thiazolidinediones as a class did not show such an association.
Therapies for Insomnia and Comorbid Chronic Obstructive Pulmonary Disease with a Focus on Ramelteon (Rozerem)
The authors discuss the relationship between sleep-related disorders and pulmonary disease and summarize the risks and benefits of medications for insomnia: the older benzodiazepine receptor agonists (e.g., flurazepam, temazepam, triazolam); the newer non-benzodiazepine agents (e.g., zolpidem, zaleplon, eszopiclone); and ramelteon, a promising melatonin receptor agonist.
Topics covered include prasugrel (Effient) for reducing cardiovascular events in patients with acute coronary syndrome; ferumoxytol injection (Feraheme) for iron-deficiency anemia in adults with chronic kidney disease; and dronedarone (Multaq) for the treatment of atrial fibrillation.